Osteopontin and Cancer: Insights into Its Role in Drug Resistance

被引：17

作者：

Hao, Chengcheng ^{[1
,2
]}

Lane, Jane ^{[2
]}

Jiang, Wen G. ^{[2
]}

机构：

[1] Capital Med Univ, Beijing Shijitan Hosp, Dept Oncol, Beijing 100038, Peoples R China

[2] Cardiff Univ, Div Canc & Genet, Cardiff China Med Res Collaborat, Sch Med, Heath Pk, Cardiff CF14 4XN, Wales

来源：

BIOMEDICINES | 2023年 / 11卷 / 01期

关键词：

osteopontin; cancer; drug resistance; molecular mechanism; LUNG-CANCER; EPIGENETIC MODIFICATIONS; EXPRESSION; CELLS; AUTOPHAGY; CISPLATIN; SENSITIVITY; BIOMARKER; HETEROGENEITY; MECHANISMS;

D O I：

10.3390/biomedicines11010197

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Cancer is one of the leading causes of mortality worldwide. Currently, drug resistance is the main obstacle in cancer treatments with the underlying mechanisms of drug resistance yet to be fully understood. Osteopontin (OPN) is a member of the integrin binding glycophosphoprotein family that is overexpressed in several tumour types. It is involved in drug transport, apoptosis, stemness, energy metabolism, and autophagy, which may contribute to drug resistance. Thus, understanding the role of OPN in cancer drug resistance could be important. This review describes the OPN-based mechanisms that might contribute to cancer drug resistance, demonstrating that OPN may be a viable target for cancer therapy to reduce drug resistance in sensitive tumours.

引用

页数：18